Paul Chaplin

Paul Chaplin is the President and CEO of Bavarian Nordic. Paul has over 15 years of experience in the biotech industry, with a focus on vaccine research and development.

Paul started their career as a Biologisch-Technischer-Assistent at the Max-Planck Insitut für Biologie. Paul then moved to LMU - Ludwig-Maximilians-Universität München, where they worked as a Senior Technician. In 2006, they joined Bavarian Nordic, where they have held various positions, including Technical Associate and President & CEO.

Under Paul's leadership, Bavarian Nordic has become a world leader in the development of cancer immunotherapies. The company's products are used by some of the world's leading cancer centers, including the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center.

Paul Chaplin is an aspiring psychotherapist who is currently receiving their basic training in psychotherapy from the Heilpraktiker Lehrinstitut Lotz.

Tommi Kainu - Executive Vice President, Chief Business Officer, Jean-Christophe May - EVP, Chief Commercial Officer, and Henrik Birk - Executive Vice President, Chief Operating Officer report to Paul Chaplin.